Camurus
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Sweden · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Ideon Science Park, Lund, Skane, 223 70,...Phone Number
+46 462865730Website
www.camurus.comRevenue
$213.2 MillionStock Symbol
CAMXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Camurus
Camurus is a Swedish biopharmaceutical company focused on improving the lives of patients with severe and chronic diseases. The company develops innovative treatments for conditions such as opioid dependence, acromegaly, neuroendocrine tumors, and other rare diseases within the central nervous system, endocrinology, oncology, and supportive care. Their diversified pipeline aims to address significant unmet medical needs, enhancing treatment outcomes and quality of life for patients. Camurus is committed to sustainability and responsible business practices while delivering better health solutions globally.Explore more
Camurus Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Camurus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Camurus had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Camurus has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Camurus has recently received funding, and reach out quickly before it becomes old news!
Check out if Camurus is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Camurus
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Camurus launches new products
Earning: See what the market has to say on Camurus recently announced quarterly report
Camurus, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Camurus as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Camurus is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Camurus is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Camurus.
Camurus Tech Stack
A closer look at the technologies used by Camurus
Most Recent Scoops
Earnings
Camurus has reported that SG&A increased in the first half of the year in preparation for the Oclase US launch, with approximately half of the increase attributable to the US and half to the rest of the world, and noted that around 20 million SEK in R&D costs were capitalized in Q2 following the Acromegaly launch, partially offsetting reported R&D expenses.
Earnings, Research & Development, Finance
Earnings
Camurus has reported that the US long-acting injectable buprenorphine segment is estimated at approximately 1.2 billion dollars on an annualized basis, growing more than 30% year on year, and that Brixadi holds an estimated 30% share of equivalent units within that segment, based on preliminary company data.
Pharmaceuticals
Earnings
Camurus has reported that Buvidal delivered a record quarter with net sales of 524 million SEK in Q2, up 12% year on year and 24% sequentially, with in-market sales rising 19% versus the same period last year and 6% quarter on quarter, reflecting broad-based growth across the Nordics, Germany, Spain, France, and the UK.
Earnings
Camurus has reported total product sales of 528 million SEK for Q2, a record quarter and the first time above half a billion SEK in a single quarter, with overall sales growing 12% year on year and 24% sequentially. The company posted an operating result of 293 million SEK, corresponding to a 42% margin, and ended the quarter with 4.1 billion SEK in cash.
Earnings, Finance
Earnings
Camurus News & Media
Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA
PDUFA target action date set to 18 December 2026 LUND, Sweden, July 17, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide...Camurus AB (publ) (CAMRF) Q2 2026 Earnings Call Transcript
Camurus AB (publ) (CAMRF) Q2 2026 Earnings Call July 15, 2026 8:00 AM EDTCompany ParticipantsFredrik Tiberg - President, CEO, CSO & DirectorAnders...Camurus announces expansion of Lilly collaboration
LUND, Sweden, June 1, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in June 2025. The decision extends Lilly's...Camurus announces expansion of Lilly collaboration
LUND, Sweden, June 1, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in June 2025. The decision extends Lilly's...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Camurus
Sign Up For FreeTo access detailed company insights
Camurus is a Swedish biopharmaceutical company focused on improving the lives of patients with severe and chronic diseases. The company develops innovative treatments for conditions such as opioid dependence, acromegaly, neuroendocrine tumors, and other rare diseases within the central nervous system, endocrinology, oncology, and supportive care. T... Read More
